| Summary: | The article discusses the implications of genomic diagnosis models for autism spectrum disorder (ASD), advocating for a "roadmap" approach over a "ticket" model. The "ticket" model, which links genomic diagnosis to access to services, may exacerbate inequities by favoring families who can afford genetic testing, while the "roadmap" model aims to guide treatment without restricting access. Despite the potential benefits of genetic testing, such as informing treatment planning and contributing to scientific knowledge, many families experience challenges, including limited understanding of testing outcomes and access barriers. The authors emphasize the need for improved equity in access to genetic testing and developmental services, highlighting systemic issues that hinder support for families affected by ASD.
|
|---|